Samir Parekh

10.0k total citations
179 papers, 2.8k citations indexed

About

Samir Parekh is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Samir Parekh has authored 179 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Hematology, 85 papers in Molecular Biology and 79 papers in Oncology. Recurrent topics in Samir Parekh's work include Multiple Myeloma Research and Treatments (96 papers), Protein Degradation and Inhibitors (46 papers) and CAR-T cell therapy research (39 papers). Samir Parekh is often cited by papers focused on Multiple Myeloma Research and Treatments (96 papers), Protein Degradation and Inhibitors (46 papers) and CAR-T cell therapy research (39 papers). Samir Parekh collaborates with scholars based in United States, United Kingdom and Canada. Samir Parekh's co-authors include Sundar Jagannath, Hearn Jay Cho, Violetta V. Leshchenko, Ajai Chari, Deepu Madduri, Alessandro Laganà, Joshua Richter, Shambavi Richard, Joshua Brody and Oliver Van Oekelen and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Samir Parekh

166 papers receiving 2.8k citations

Peers

Countries citing papers authored by Samir Parekh

Since Specialization

Citations

This map shows the geographic impact of Samir Parekh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samir Parekh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samir Parekh more than expected).

Fields of papers citing papers by Samir Parekh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samir Parekh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samir Parekh. The network helps show where Samir Parekh may publish in the future.

Co-authorship network of co-authors of Samir Parekh

This figure shows the co-authorship network connecting the top 25 collaborators of Samir Parekh. A scholar is included among the top collaborators of Samir Parekh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samir Parekh. Samir Parekh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma 2025 ·Haematologica ·(unknown), (unknown), (unknown), Charles Gleason, John F. Crary, Lusheng Song, Jin Park, (unknown), (unknown), (unknown), Isaac E. Stillman, Joshua LaBaer, Adolfo Aleman, Sundar Jagannath, Samir Parekh	1
2	Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy 2025 ·Clinical Cancer Research ·(unknown), (unknown), (unknown), (unknown), Adolfo Aleman, (unknown), Erin Moshier, Adriana Rossi, Shambavi Richard, Gurbakhash Kaur, Joshua Richter, Larysa Sanchez, Cesar Rodriguez, Hearn Jay Cho, Shafinaz Hussein, (unknown), Lewis R. Silverman, Sundar Jagannath, Samir Parekh, Santiago Thibaud	1
3	Comparison of MRI, [18F]FDG-PET/CT, and [18F]FDG-PET/MRI for Initial Staging of Multiple Myeloma 2025 ·Clinical Nuclear Medicine ·Mickaël Tordjman, Murat Yüce, (unknown), Giuseppe Petralia, Roberto C. Delgado Bolton, (unknown), Amish Doshi, (unknown), Xueyan Mei, Laurent Dercle, Himanshu Joshi, Christina Messiou, Dow‐Mu Koh, Samir Parekh, Bachir Taouli	0
4	Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance 2024 ·Blood ·(unknown), Heng‐Huan Lee, Ravi Prakash Shukla, Violetta V. Leshchenko, Fanye Meng, Fangfang Yan, Yang Liu, H. Ümit Kanıskan, Jian Jin, Lapo Alinari, Michael Wang, Samir Parekh	1
5	Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma 2024 ·Journal for ImmunoTherapy of Cancer ·David G. Coffey, Keren Osman, Adolfo Aleman, (unknown), (unknown), (unknown), (unknown), Seunghee Kim‐Schulze, Sacha Gnjatic, Ajai Chari, Samir Parekh, Sundar Jagannath, Hearn Jay Cho	5
6	Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study 2023 ·Blood ·Lucia Chen, Santiago Thibaud, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa Sanchez, Cesar Rodriguez, Adriana Rossi, Shambavi Richard, Samir Parekh, Sundar Jagannath	0
7	A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy 2021 ·Cancer Discovery ·Ranjan Upadhyay, Jonathan Boiarsky, (unknown), Judit Svensson‐Arvelund, Matthew Lin, Aleksandra Wroblewska, Sherry Bhalla, Nathalie Scholler, Adrian Bot, John M. Rossi, Norah Sadek, Samir Parekh, Alessandro Laganà, Alessia Baccarini, Miriam Mérad, Brian D. Brown, Joshua Brody	125
8	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Guido Lancman, (unknown), (unknown), Samantha E. Jacobs, John T. Doucette, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Joshua Richter, Ajai Chari	18
9	The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma 2021 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Kunal K. Sindhu, Erin Moshier, Joshua Richter, Shambavi Richard, Ajai Chari, Larysa Sanchez, Samir Parekh, Hearn Jay Cho, Sundar Jagannath, Kavita V. Dharmarajan	6
10	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy 2021 ·Nature Medicine ·Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, (unknown), Deepu Madduri, Somali Gavane, Julie Teruya‐Feldstein, John F. Crary, Mary Fowkes, Charles B. Stacy, Seunghee Kim‐Schulze, Adeeb Rahman, Alessandro Laganà, Joshua Brody, Miriam Mérad, Sundar Jagannath, Samir Parekh	151
11	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Siyang Leng, Erin Moshier, Douglas Tremblay, Liangyuan Hu, Noa Biran, (unknown), Samir Parekh, (unknown), Deepu Madduri, Joshua Richter, Bart Barlogie, Sundar Jagannath, Ajai Chari	2
12	Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma 2020 ·Clinical Cancer Research ·William E. Pierceall, Michael Amatangelo, Nizar J. Bahlis, David S. Siegel, Adeeb Rahman, Oliver Van Oekelen, Paola Neri, Mary H. Young, (unknown), Natalya V. Serbina, Samir Parekh, Amit Agarwal, Anjan Thakurta	27
13	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma 2019 ·Clinical Cancer Research ·Deepak Perumal, Naoko Imai, Alessandro Laganà, John P. Finnigan, David T. Melnekoff, Violetta V. Leshchenko, Alexander Solovyov, Deepu Madduri, Ajai Chari, Hearn Jay Cho, Joel T. Dudley, Joshua Brody, Sundar Jagannath, Benjamin D. Greenbaum, Sacha Gnjatic, Nina Bhardwaj, Samir Parekh	59
14	Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients 2019 ·Blood ·Michael Amatangelo, Oliver Van Oekelen, Adeeb Rahman, Alessandro Laganà, Sarah Gooding, Hervé Avet‐Loiseau, Udo Oppermann, William E. Pierceall, Anjan Thakurta, Samir Parekh	9
15	Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma 2016 ·Cancer Research ·Deepak Perumal, (unknown), Violetta V. Leshchenko, Zewei Jiang, Sai Krishna Athaluri Divakar, Hearn Jay Cho, Ajai Chari, Joshua Brody, M. V. Ramana Reddy, Weijia Zhang, E. Premkumar Reddy, Sundar Jagannath, Samir Parekh	27
16	An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL 2016 ·Blood ·(unknown), Jingwei Yu, Boris Bartholdy, Zijun Y. Xu‐Monette, (unknown), Fei Yuan, Hongshan Chen, B. Belinda Ding, Zhihua Yao, Bhaskar C. Das, Yiyu Zou, Ken H. Young, Samir Parekh, B. Hilda Ye	48
17	Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma 2013 ·Clinical Cancer Research ·Violetta V. Leshchenko, (unknown), Zewei Jiang, (unknown), Samir Parekh	17
18	Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma 2012 ·Clinical Cancer Research ·Adam M. Petrich, Violetta V. Leshchenko, (unknown), Bing Xia, (unknown), Netha Ulahannan, Shanisha Gordon, Melissa Fazzari, B. Hilda Ye, Joseph A. Sparano, Samir Parekh	48
19	Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome 2009 ·Blood ·Britta Will, Masahiro Kawahara, (unknown), Ingmar Bruns, Samir Parekh, Connie L. Erickson‐Miller, Manuel Aivado, Amit Verma, Ulrich Steidl	95
20	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms 2007 ·Blood ·Samir Parekh, José M. Polo, Rita Shaknovich, Przemysław Juszczyński, Paola R. Lev, Stella Maris Ranuncolo, (unknown), Ulf Klein, Giorgio Cattoretti, Riccardo Dalla Favera, Margaret A. Shipp, Ari Melnick	105

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact